- Home
- TSAT vs FDMT Comparison
TSAT vs FDMT Comparison
Compare TSAT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSAT | FDMT |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.1M | 513.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TSAT | FDMT |
|---|---|---|
| Price | $31.08 | $8.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $34.13 |
| AVG Volume (30 Days) | 110.8K | ★ 753.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.81 | $2.24 |
| 52 Week High | $36.85 | $12.34 |
Technical Indicators
Market Signals| Indicator | TSAT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 43.30 |
| Support Level | $28.22 | $8.11 |
| Resistance Level | $30.83 | $8.80 |
| Average True Range (ATR) | 2.37 | 0.57 |
| MACD | 0.31 | -0.14 |
| Stochastic Oscillator | 51.54 | 14.85 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.